25 XP   0   0   10

Tibet Aim Pharm Inc
Buy, Hold or Sell?

Let's analyse Tibet Aim Pharm Inc together

PenkeI guess you are interested in Tibet Aim Pharm Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Tibet Aim Pharm Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Tibet Aim Pharm Inc

I send you an email if I find something interesting about Tibet Aim Pharm Inc.

Quick analysis of Tibet Aim Pharm Inc (30 sec.)










What can you expect buying and holding a share of Tibet Aim Pharm Inc? (30 sec.)

How much money do you get?

How much money do you get?
¥0.02
When do you have the money?
1 year
How often do you get paid?
93.5%

What is your share worth?

Current worth
¥3.98
Expected worth in 1 year
¥4.17
How sure are you?
96.8%

+ What do you gain per year?

Total Gains per Share
¥0.30
Return On Investment
3.4%

For what price can you sell your share?

Current Price per Share
¥8.91
Expected price per share
¥5.57 - ¥9.06
How sure are you?
50%

1. Valuation of Tibet Aim Pharm Inc (5 min.)




Live pricePrice per Share (EOD)

¥8.91

Intrinsic Value Per Share

¥-0.29 - ¥-0.57

Total Value Per Share

¥3.69 - ¥3.41

2. Growth of Tibet Aim Pharm Inc (5 min.)




Is Tibet Aim Pharm Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$104.8m$99.6m$5.1m4.9%

How much money is Tibet Aim Pharm Inc making?

Current yearPrevious yearGrowGrow %
Making money$1.6m$1.6m$6.5k0.4%
Net Profit Margin5.6%5.8%--

How much money comes from the company's main activities?

3. Financial Health of Tibet Aim Pharm Inc (5 min.)




What can you expect buying and holding a share of Tibet Aim Pharm Inc? (5 min.)

Welcome investor! Tibet Aim Pharm Inc's management wants to use your money to grow the business. In return you get a share of Tibet Aim Pharm Inc.

What can you expect buying and holding a share of Tibet Aim Pharm Inc?

First you should know what it really means to hold a share of Tibet Aim Pharm Inc. And how you can make/lose money.

Speculation

The Price per Share of Tibet Aim Pharm Inc is ¥8.91. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Tibet Aim Pharm Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Tibet Aim Pharm Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥3.98. Based on the TTM, the Book Value Change Per Share is ¥0.05 per quarter. Based on the YOY, the Book Value Change Per Share is ¥0.05 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.03 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Tibet Aim Pharm Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.010.1%0.010.1%0.010.1%0.010.1%0.010.1%
Usd Book Value Change Per Share-0.01-0.1%0.010.1%0.010.1%0.010.1%0.020.2%
Usd Dividend Per Share0.010.2%0.000.0%0.010.2%0.010.1%0.010.1%
Usd Total Gains Per Share0.010.1%0.010.1%0.020.2%0.010.1%0.020.3%
Usd Price Per Share1.59-1.50-1.45-1.43-1.63-
Price to Earnings Ratio55.99-57.59-67.74-70.70-63.73-
Price-to-Total Gains Ratio211.93-176.25-124.81-262.59-247.45-
Price to Book Ratio2.89-2.73-2.78-2.89-3.55-
Price-to-Total Gains Ratio211.93-176.25-124.81-262.59-247.45-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.230471
Number of shares812
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share0.010.01
Usd Total Gains Per Share0.010.01
Gains per Quarter (812 shares)8.4510.80
Gains per Year (812 shares)33.8143.19
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1132124251833
2254258503676
33863927555119
4518512610073162
56310616012591205
676127194150109248
789148228175128291
8101169262200146334
9114190296225164377
10127212330250182420

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%30.01.00.096.8%30.01.00.096.8%
Book Value Change Per Share3.01.00.075.0%9.03.00.075.0%15.05.00.075.0%23.07.01.074.2%23.07.01.074.2%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%29.00.02.093.5%29.00.02.093.5%
Total Gains per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%30.01.00.096.8%30.01.00.096.8%

Fundamentals of Tibet Aim Pharm Inc

About Tibet Aim Pharm Inc

Tibet AIM Pharm. Inc. engages in the research and development, manufacturing, and sale of medical products in China. The company's products include Miglitol tablets for diabetes; Gualoupi injection for coronary disease; Oxytocin injection for gynecology and obstetrics; and NalMefene injection for various acute poisoning, such as alcohol, organic phosphor, CO, sedative-hypnotic, opioid substance, serious infection, shock, fainting, and brain, as well as coma, spinal cord injury, cerebral infarction, hemorrhage, etc. It also provides Carbetocin injections for prevention of postpartum hemorrhage; Domperidone tablets for treatment of indigestion, abdominal bloating, belching, nausea, vomiting, and abdominal distension and pain; Montmorillonite powder for chronic diarrhea; Hongjin Xiaojie tablets and Aceclofenac Enteric-Coated tablets, as well as for the treatment of antibiotics, antiallergic, and digestive systems. Tibet AIM Pharm. Inc. was founded in 2003 and is headquartered in Beijing, China.

Fundamental data was last updated by Penke on 2024-04-14 19:59:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Tibet Aim Pharm Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Tibet Aim Pharm Inc earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Tibet Aim Pharm Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 6.1% means that ¥0.06 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Tibet Aim Pharm Inc:

  • The MRQ is 6.1%. The company is making a profit. +1
  • The TTM is 5.6%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ6.1%TTM5.6%+0.5%
TTM5.6%YOY5.8%-0.2%
TTM5.6%5Y5.7%-0.1%
5Y5.7%10Y7.1%-1.4%
1.1.2. Return on Assets

Shows how efficient Tibet Aim Pharm Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Tibet Aim Pharm Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • 1.0% Return on Assets means that Tibet Aim Pharm Inc generated ¥0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Tibet Aim Pharm Inc:

  • The MRQ is 1.0%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 1.2%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.0%TTM1.2%-0.2%
TTM1.2%YOY1.4%-0.2%
TTM1.2%5Y1.2%0.0%
5Y1.2%10Y1.4%-0.2%
1.1.3. Return on Equity

Shows how efficient Tibet Aim Pharm Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Tibet Aim Pharm Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • 1.3% Return on Equity means Tibet Aim Pharm Inc generated ¥0.01 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Tibet Aim Pharm Inc:

  • The MRQ is 1.3%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 1.6%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.3%TTM1.6%-0.3%
TTM1.6%YOY1.6%-0.1%
TTM1.6%5Y1.5%+0.1%
5Y1.5%10Y1.9%-0.4%

1.2. Operating Efficiency of Tibet Aim Pharm Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Tibet Aim Pharm Inc is operating .

  • Measures how much profit Tibet Aim Pharm Inc makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Tibet Aim Pharm Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of -0.3% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Tibet Aim Pharm Inc:

  • The MRQ is -0.3%. The company is operating very inefficient. -2
  • The TTM is 4.9%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ-0.3%TTM4.9%-5.2%
TTM4.9%YOY5.7%-0.8%
TTM4.9%5Y5.9%-1.0%
5Y5.9%10Y4.2%+1.7%
1.2.2. Operating Ratio

Measures how efficient Tibet Aim Pharm Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.35 means that the operating costs are ¥1.35 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Tibet Aim Pharm Inc:

  • The MRQ is 1.346. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.456. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.346TTM1.456-0.111
TTM1.456YOY1.515-0.058
TTM1.4565Y1.587-0.131
5Y1.58710Y1.194+0.393

1.3. Liquidity of Tibet Aim Pharm Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Tibet Aim Pharm Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.40 means the company has ¥2.40 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Tibet Aim Pharm Inc:

  • The MRQ is 2.404. The company is able to pay all its short-term debts. +1
  • The TTM is 2.295. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.404TTM2.295+0.109
TTM2.295YOY3.171-0.876
TTM2.2955Y2.650-0.356
5Y2.65010Y1.923+0.727
1.3.2. Quick Ratio

Measures if Tibet Aim Pharm Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Tibet Aim Pharm Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.02 means the company can pay off ¥1.02 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Tibet Aim Pharm Inc:

  • The MRQ is 1.024. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.020. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.024TTM1.020+0.004
TTM1.020YOY1.474-0.454
TTM1.0205Y1.102-0.082
5Y1.10210Y1.092+0.010

1.4. Solvency of Tibet Aim Pharm Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Tibet Aim Pharm Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Tibet Aim Pharm Inc to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.23 means that Tibet Aim Pharm Inc assets are financed with 22.9% credit (debt) and the remaining percentage (100% - 22.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Tibet Aim Pharm Inc:

  • The MRQ is 0.229. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.249. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.229TTM0.249-0.020
TTM0.249YOY0.160+0.088
TTM0.2495Y0.202+0.047
5Y0.20210Y0.195+0.007
1.4.2. Debt to Equity Ratio

Measures if Tibet Aim Pharm Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Tibet Aim Pharm Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 29.8% means that company has ¥0.30 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Tibet Aim Pharm Inc:

  • The MRQ is 0.298. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.333. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.298TTM0.333-0.035
TTM0.333YOY0.194+0.139
TTM0.3335Y0.257+0.076
5Y0.25710Y0.250+0.007

2. Market Valuation of Tibet Aim Pharm Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Tibet Aim Pharm Inc generates.

  • Above 15 is considered overpriced but always compare Tibet Aim Pharm Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 55.99 means the investor is paying ¥55.99 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Tibet Aim Pharm Inc:

  • The EOD is 43.309. Based on the earnings, the company is overpriced. -1
  • The MRQ is 55.995. Based on the earnings, the company is expensive. -2
  • The TTM is 57.587. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD43.309MRQ55.995-12.686
MRQ55.995TTM57.587-1.592
TTM57.587YOY67.740-10.154
TTM57.5875Y70.703-13.116
5Y70.70310Y63.731+6.972
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Tibet Aim Pharm Inc:

  • The EOD is -752.900. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -973.446. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -241.424. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-752.900MRQ-973.446+220.546
MRQ-973.446TTM-241.424-732.022
TTM-241.424YOY-13.271-228.153
TTM-241.4245Y-15.650-225.774
5Y-15.65010Y-11.295-4.355
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Tibet Aim Pharm Inc is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Tibet Aim Pharm Inc:

  • The EOD is 2.238. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.894. Based on the equity, the company is underpriced. +1
  • The TTM is 2.731. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.238MRQ2.894-0.656
MRQ2.894TTM2.731+0.163
TTM2.731YOY2.783-0.052
TTM2.7315Y2.887-0.156
5Y2.88710Y3.552-0.665
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Tibet Aim Pharm Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.0460.047-198%0.046-202%0.041-214%0.128-136%
Book Value Per Share--3.9803.979+0%3.778+5%3.606+10%3.213+24%
Current Ratio--2.4042.295+5%3.171-24%2.650-9%1.923+25%
Debt To Asset Ratio--0.2290.249-8%0.160+43%0.202+13%0.195+18%
Debt To Equity Ratio--0.2980.333-10%0.194+54%0.257+16%0.250+19%
Dividend Per Share--0.1010.028+257%0.101-1%0.056+81%0.044+126%
Eps--0.0510.061-16%0.061-16%0.053-3%0.056-8%
Free Cash Flow Per Share---0.0030.069-104%0.172-102%0.047-106%0.026-111%
Free Cash Flow To Equity Per Share---0.313-0.011-97%0.205-253%0.020-1638%0.048-752%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---0.572--------
Intrinsic Value_10Y_min---0.287--------
Intrinsic Value_1Y_max--0.432--------
Intrinsic Value_1Y_min--0.425--------
Intrinsic Value_3Y_max--0.926--------
Intrinsic Value_3Y_min--0.891--------
Intrinsic Value_5Y_max--0.969--------
Intrinsic Value_5Y_min--0.932--------
Market Cap1698940980.000-29%2196610560.0002072692119.375+6%2008387984.688+9%1983665219.813+11%2260114968.911-3%
Net Profit Margin--0.0610.056+8%0.058+5%0.057+6%0.071-14%
Operating Margin---0.0030.049-107%0.057-106%0.059-106%0.042-108%
Operating Ratio--1.3461.456-8%1.515-11%1.587-15%1.194+13%
Pb Ratio2.238-29%2.8942.731+6%2.783+4%2.887+0%3.552-19%
Pe Ratio43.309-29%55.99557.587-3%67.740-17%70.703-21%63.731-12%
Price Per Share8.910-29%11.52010.870+6%10.518+10%10.362+11%11.826-3%
Price To Free Cash Flow Ratio-752.900+23%-973.446-241.424-75%-13.271-99%-15.650-98%-11.295-99%
Price To Total Gains Ratio163.917-29%211.933176.248+20%124.811+70%262.593-19%247.445-14%
Quick Ratio--1.0241.020+0%1.474-31%1.102-7%1.092-6%
Return On Assets--0.0100.012-14%0.014-28%0.012-15%0.014-30%
Return On Equity--0.0130.016-16%0.016-20%0.015-12%0.019-31%
Total Gains Per Share--0.0540.075-28%0.147-63%0.096-44%0.173-69%
Usd Book Value--104815921.916104789848.186+0%99628490.946+5%95320820.245+10%84858519.097+24%
Usd Book Value Change Per Share---0.0060.007-198%0.006-202%0.006-214%0.018-136%
Usd Book Value Per Share--0.5500.550+0%0.522+5%0.498+10%0.444+24%
Usd Dividend Per Share--0.0140.004+257%0.014-1%0.008+81%0.006+126%
Usd Eps--0.0070.008-16%0.008-16%0.007-3%0.008-8%
Usd Free Cash Flow---77906.6971814615.336-104%4535290.171-102%1238335.611-106%644794.648-112%
Usd Free Cash Flow Per Share--0.0000.010-104%0.024-102%0.006-106%0.004-111%
Usd Free Cash Flow To Equity Per Share---0.043-0.001-97%0.028-253%0.003-1638%0.007-752%
Usd Market Cap234623749.338-29%303351918.336286238781.686+6%277358380.685+9%273944166.856+11%312121877.207-3%
Usd Price Per Share1.230-29%1.5911.501+6%1.452+10%1.431+11%1.633-3%
Usd Profit--1354374.4801615002.023-16%1608492.983-16%1403261.890-3%1470141.940-8%
Usd Revenue--22353592.81627732817.213-19%27588332.071-19%23678269.271-6%21766339.256+3%
Usd Total Gains Per Share--0.0080.010-28%0.020-63%0.013-44%0.024-69%
 EOD+3 -5MRQTTM+17 -18YOY+11 -245Y+12 -2310Y+11 -24

3.2. Fundamental Score

Let's check the fundamental score of Tibet Aim Pharm Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1543.309
Price to Book Ratio (EOD)Between0-12.238
Net Profit Margin (MRQ)Greater than00.061
Operating Margin (MRQ)Greater than0-0.003
Quick Ratio (MRQ)Greater than11.024
Current Ratio (MRQ)Greater than12.404
Debt to Asset Ratio (MRQ)Less than10.229
Debt to Equity Ratio (MRQ)Less than10.298
Return on Equity (MRQ)Greater than0.150.013
Return on Assets (MRQ)Greater than0.050.010
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Tibet Aim Pharm Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.955
Ma 20Greater thanMa 508.272
Ma 50Greater thanMa 1008.211
Ma 100Greater thanMa 2009.639
OpenGreater thanClose8.880
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-09-302022-12-312023-03-312023-06-302023-09-30
Minority Interest  -20-1,725-1,7451,630-115-340-45651559
EBIT  14,90614,92329,828-20,0999,729-3,6496,080-6,641-561



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in CNY. All numbers in thousands.

Summary
Total Assets983,957
Total Liabilities224,971
Total Stockholder Equity753,772
 As reported
Total Liabilities 224,971
Total Stockholder Equity+ 753,772
Total Assets = 983,957

Assets

Total Assets983,957
Total Current Assets519,833
Long-term Assets464,124
Total Current Assets
Cash And Cash Equivalents 227,589
Short-term Investments 70,000
Net Receivables 151,539
Inventory 54,729
Other Current Assets 15,976
Total Current Assets  (as reported)519,833
Total Current Assets  (calculated)519,833
+/- 0
Long-term Assets
Property Plant Equipment 353,233
Goodwill 36,473
Intangible Assets 26,806
Other Assets 5,157
Long-term Assets  (as reported)464,124
Long-term Assets  (calculated)421,668
+/- 42,456

Liabilities & Shareholders' Equity

Total Current Liabilities216,273
Long-term Liabilities8,697
Total Stockholder Equity753,772
Total Current Liabilities
Short Long Term Debt 10,000
Accounts payable 148,844
Other Current Liabilities 50,277
Total Current Liabilities  (as reported)216,273
Total Current Liabilities  (calculated)209,122
+/- 7,152
Long-term Liabilities
Other Liabilities 8,697
Long-term Liabilities  (as reported)8,697
Long-term Liabilities  (calculated)8,697
+/- 0
Total Stockholder Equity
Common Stock190,678
Retained Earnings 326,783
Other Stockholders Equity 3,649
Total Stockholder Equity (as reported)753,772
Total Stockholder Equity (calculated)521,110
+/- 232,661
Other
Capital Stock190,678
Common Stock Shares Outstanding 190,678
Net Invested Capital 763,772
Net Tangible Assets 690,493
Net Working Capital 303,560
Property Plant and Equipment Gross 353,233



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312014-12-312013-12-31
> Total Assets 
153,097
268,418
397,696
0
422,213
416,924
646,361
654,320
666,260
671,195
733,291
733,493
762,340
755,495
757,934
800,043
780,323
803,738
835,406
769,755
897,542
833,478
908,087
876,006
808,019
804,911
824,473
835,486
860,958
922,221
1,018,205
1,015,183
1,022,603
983,957
983,9571,022,6031,015,1831,018,205922,221860,958835,486824,473804,911808,019876,006908,087833,478897,542769,755835,406803,738780,323800,043757,934755,495762,340733,493733,291671,195666,260654,320646,361416,924422,2130397,696268,418153,097
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
503,480
489,175
464,217
492,096
426,833
385,291
400,568
328,668
459,431
376,725
450,253
422,383
359,835
329,196
362,174
377,539
409,026
476,201
575,009
578,091
552,218
519,833
519,833552,218578,091575,009476,201409,026377,539362,174329,196359,835422,383450,253376,725459,431328,668400,568385,291426,833492,096464,217489,175503,480000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
84,454
87,126
238,707
185,252
195,859
99,430
159,913
84,444
200,744
151,708
205,322
159,445
142,868
141,643
182,725
126,392
171,726
200,822
321,283
252,346
206,587
227,589
227,589206,587252,346321,283200,822171,726126,392182,725141,643142,868159,445205,322151,708200,74484,444159,91399,430195,859185,252238,70787,12684,454000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
170,000
0
0
0
35,000
0
30,000
0
0
0
0
0
0
0
0
50,000
50,000
100,000
0
100,000
150,151
70,000
70,000150,151100,0000100,00050,00050,0000000000030,000035,000000170,000000000000000
       Net Receivables 
16,221
44,194
76,197
0
108,730
0
112,122
96,453
105,205
114,412
171,894
167,552
184,278
158,522
188,109
66,456
64,615
62,326
95,194
189,883
206,401
180,332
218,620
219,060
162,488
141,133
137,403
153,208
137,394
132,799
201,874
175,995
137,607
151,539
151,539137,607175,995201,874132,799137,394153,208137,403141,133162,488219,060218,620180,332206,401189,88395,19462,32664,61566,456188,109158,522184,278167,552171,894114,412105,20596,453112,1220108,730076,19744,19416,221
       Other Current Assets 
7,649
44,048
47,513
0
22,820
202,422
21,890
127,771
28,361
159,297
11,881
34,763
31,417
213,612
7,903
90,510
39,891
65,259
85,637
26,031
23,091
20,781
5,612
13,132
21,410
16,518
5,144
13,325
7,151
9,934
6,298
5,791
6,891
15,976
15,9766,8915,7916,2989,9347,15113,3255,14416,51821,41013,1325,61220,78123,09126,03185,63765,25939,89190,5107,903213,61231,41734,76311,881159,29728,361127,77121,890202,42222,820047,51344,0487,649
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
307,946
353,490
418,447
434,838
441,087
438,110
456,753
457,835
453,624
448,185
475,714
462,300
457,947
451,932
446,021
443,195
437,092
470,385
464,124
464,124470,385437,092443,195446,021451,932457,947462,300475,714448,185453,624457,835456,753438,110441,087434,838418,447353,490307,946000000000000000
       Property Plant Equipment 
26,240
45,373
135,404
0
139,300
0
139,813
145,363
146,754
169,382
177,360
176,755
176,541
200,373
198,392
198,457
274,066
326,740
368,147
366,265
374,232
395,988
396,146
393,149
389,500
386,766
378,961
375,609
371,953
367,963
364,848
360,839
356,892
353,233
353,233356,892360,839364,848367,963371,953375,609378,961386,766389,500393,149396,146395,988374,232366,265368,147326,740274,066198,457198,392200,373176,541176,755177,360169,382146,754145,363139,8130139,3000135,40445,37326,240
       Goodwill 
7,667
7,667
7,667
0
7,667
0
7,667
7,667
7,667
7,667
7,667
7,667
7,667
7,667
7,667
7,667
7,667
7,667
7,667
7,667
7,667
7,667
7,667
7,667
7,667
36,473
36,473
36,473
36,473
36,473
36,473
36,473
36,473
36,473
36,47336,47336,47336,47336,47336,47336,47336,47336,4737,6677,6677,6677,6677,6677,6677,6677,6677,6677,6677,6677,6677,6677,6677,6677,6677,6677,6677,66707,66707,6677,6677,667
       Intangible Assets 
15,677
18,578
33,664
0
33,260
0
32,933
32,610
32,279
32,200
31,872
31,544
25,691
25,511
29,104
46,515
24,156
50,228
46,947
46,411
47,362
46,351
43,610
42,134
40,669
41,846
37,248
35,621
34,084
32,593
31,102
29,612
28,134
26,806
26,80628,13429,61231,10232,59334,08435,62137,24841,84640,66942,13443,61046,35147,36246,41146,94750,22824,15646,51529,10425,51125,69131,54431,87232,20032,27932,61032,933033,260033,66418,57815,677
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
52,272
21,723
29,826
10,040
18,577
6,476
400,440
4,731
5,007
5,042
4,877
3,922
4,825
4,485
4,485
4,178
4,187
160
143
1431604,1874,1784,4854,4854,8253,9224,8775,0425,0074,731400,4406,47618,57710,04029,82621,72352,272000000000000000
> Total Liabilities 
81,433
89,296
149,445
0
149,384
133,089
90,925
93,328
100,876
93,624
128,762
122,815
153,682
151,398
139,533
174,995
155,612
179,075
183,237
110,585
237,817
168,929
220,941
183,048
125,007
112,736
104,363
106,547
147,337
199,200
268,208
256,795
254,785
224,971
224,971254,785256,795268,208199,200147,337106,547104,363112,736125,007183,048220,941168,929237,817110,585183,237179,075155,612174,995139,533151,398153,682122,815128,76293,624100,87693,32890,925133,089149,3840149,44589,29681,433
   > Total Current Liabilities 
81,433
89,046
107,495
0
108,519
92,016
88,895
91,341
98,128
90,938
126,140
120,256
151,184
148,964
137,661
173,186
153,866
177,391
180,305
107,715
235,010
164,685
218,271
180,387
119,703
107,600
99,347
101,467
142,521
194,576
261,914
247,669
245,880
216,273
216,273245,880247,669261,914194,576142,521101,46799,347107,600119,703180,387218,271164,685235,010107,715180,305177,391153,866173,186137,661148,964151,184120,256126,14090,93898,12891,34188,89592,016108,5190107,49589,04681,433
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
100,000
70,000
70,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000070,00070,000100,000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
100,000
70,000
70,000
70,000
0
110,000
40,000
40,000
40,000
0
0
0
0
0
50,000
50,051
50,000
50,000
10,000
10,00050,00050,00050,05150,0000000040,00040,00040,000110,000070,00070,00070,000100,000000000000000000
       Accounts payable 
3,721
5,397
19,272
0
3,430
0
14,300
8,503
8,946
8,595
8,147
4,965
11,040
8,498
11,225
16,572
24,318
36,131
23,655
15,702
12,861
24,185
39,196
25,864
18,437
14,641
17,201
29,287
44,810
64,814
127,013
116,496
131,272
148,844
148,844131,272116,496127,01364,81444,81029,28717,20114,64118,43725,86439,19624,18512,86115,70223,65536,13124,31816,57211,2258,49811,0404,9658,1478,5958,9468,50314,30003,430019,2725,3973,721
       Other Current Liabilities 
57,712
73,650
68,222
0
85,088
92,016
64,596
72,838
79,182
72,344
117,993
105,290
81,384
98,037
74,700
53,697
54,976
99,978
74,922
88,207
104,114
96,606
120,068
108,378
89,712
86,572
63,581
65,109
74,286
71,002
67,999
65,342
47,095
50,277
50,27747,09565,34267,99971,00274,28665,10963,58186,57289,712108,378120,06896,606104,11488,20774,92299,97854,97653,69774,70098,03781,384105,290117,99372,34479,18272,83864,59692,01685,088068,22273,65057,712
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,809
1,746
1,683
2,932
2,869
2,807
4,244
2,670
2,661
5,304
5,135
5,016
5,080
4,816
4,624
6,294
9,126
8,905
8,697
8,6978,9059,1266,2944,6244,8165,0805,0165,1355,3042,6612,6704,2442,8072,8692,9321,6831,7461,809000000000000000
       Other Liabilities 
0
250
1,950
0
1,865
41,073
2,030
1,988
2,748
2,686
2,623
2,560
2,497
2,434
1,872
1,809
1,746
1,683
2,932
2,869
2,807
4,244
2,670
2,575
5,217
5,049
5,016
5,080
4,816
4,624
6,294
9,126
8,905
8,697
8,6978,9059,1266,2944,6244,8165,0805,0165,0495,2172,5752,6704,2442,8072,8692,9321,6831,7461,8091,8722,4342,4972,5602,6232,6862,7481,9882,03041,0731,86501,9502500
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
21,233
11,815
17,088
17,853
18,865
23,708
14,586
14,928
3,635
4,086
2,076
2,107
2,137
2,302
3,569
3,191
2,911
2,482
1,784
1,338
892
446
4468921,3381,7842,4822,9113,1913,5692,3022,1372,1072,0764,0863,63514,92814,58623,70818,86517,85317,08811,81521,233000000000000
> Total Stockholder Equity
65,030
179,122
248,251
248,251
272,829
283,836
555,436
560,991
565,384
577,571
604,529
610,678
608,659
604,097
618,401
625,048
624,711
624,664
652,169
659,170
659,725
664,549
687,146
692,958
683,013
690,411
717,390
726,106
710,684
720,064
745,294
753,570
762,544
753,772
753,772762,544753,570745,294720,064710,684726,106717,390690,411683,013692,958687,146664,549659,725659,170652,169624,664624,711625,048618,401604,097608,659610,678604,529577,571565,384560,991555,436283,836272,829248,251248,251179,12265,030
   Common Stock
50,000
135,000
142,290
0
142,290
283,836
189,720
189,720
189,720
189,720
189,720
189,720
189,720
189,720
189,720
189,720
189,720
189,720
193,210
193,210
191,769
191,769
191,769
191,769
191,190
191,190
191,190
191,190
190,682
190,682
190,682
190,682
190,678
190,678
190,678190,678190,682190,682190,682190,682191,190191,190191,190191,190191,769191,769191,769191,769193,210193,210189,720189,720189,720189,720189,720189,720189,720189,720189,720189,720189,720189,720283,836142,2900142,290135,00050,000
   Retained Earnings 
15,030
36,218
86,248
0
110,825
0
141,606
147,162
151,555
163,742
190,700
196,848
194,830
190,267
204,571
193,559
193,235
193,092
236,209
242,178
241,727
245,630
269,629
274,885
264,531
271,486
296,834
305,362
289,800
299,072
321,962
330,325
336,044
326,783
326,783336,044330,325321,962299,072289,800305,362296,834271,486264,531274,885269,629245,630241,727242,178236,209193,092193,235193,559204,571190,267194,830196,848190,700163,742151,555147,162141,6060110,825086,24836,21815,030
   Capital Surplus 0000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
80
68
163
97
118
114
64
15
22
6
10
-4
-6
-15
93
-8
-95
3,162
3,649
3,6493,162-95-893-15-6-4106221564114118971636880000000000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue803,268
Cost of Revenue-425,341
Gross Profit377,926377,926
 
Operating Income (+$)
Gross Profit377,926
Operating Expense-747,302
Operating Income55,966-369,376
 
Operating Expense (+$)
Research Development21,685
Selling General Administrative299,171
Selling And Marketing Expenses-
Operating Expense747,302320,856
 
Net Interest Income (+$)
Interest Income2,267
Interest Expense-1,625
Other Finance Cost-189
Net Interest Income832
 
Pretax Income (+$)
Operating Income55,966
Net Interest Income832
Other Non-Operating Income Expenses-
Income Before Tax (EBT)57,64755,966
EBIT - interestExpense = -1,625
46,778
48,403
Interest Expense1,625
Earnings Before Interest and Taxes (EBIT)-59,272
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax57,647
Tax Provision-8,612
Net Income From Continuing Ops49,03549,035
Net Income46,778
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--832
 

Technical Analysis of Tibet Aim Pharm Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Tibet Aim Pharm Inc. The general trend of Tibet Aim Pharm Inc is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Tibet Aim Pharm Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Tibet Aim Pharm Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 8.95 < 9.0153 < 9.06.

The bearish price targets are: 6.98 > 5.57.

Tweet this
Tibet Aim Pharm Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Tibet Aim Pharm Inc. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Tibet Aim Pharm Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Tibet Aim Pharm Inc. The current macd is 0.04196443.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Tibet Aim Pharm Inc price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Tibet Aim Pharm Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Tibet Aim Pharm Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Tibet Aim Pharm Inc Daily Moving Average Convergence/Divergence (MACD) ChartTibet Aim Pharm Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Tibet Aim Pharm Inc. The current adx is 17.64.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Tibet Aim Pharm Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Tibet Aim Pharm Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Tibet Aim Pharm Inc. The current sar is 7.1876224.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Tibet Aim Pharm Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Tibet Aim Pharm Inc. The current rsi is 58.95. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Tibet Aim Pharm Inc Daily Relative Strength Index (RSI) ChartTibet Aim Pharm Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Tibet Aim Pharm Inc. The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 5/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Tibet Aim Pharm Inc price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Tibet Aim Pharm Inc Daily Stochastic Oscillator ChartTibet Aim Pharm Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Tibet Aim Pharm Inc. The current cci is 99.50.

Tibet Aim Pharm Inc Daily Commodity Channel Index (CCI) ChartTibet Aim Pharm Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Tibet Aim Pharm Inc. The current cmo is 29.52.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Tibet Aim Pharm Inc Daily Chande Momentum Oscillator (CMO) ChartTibet Aim Pharm Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Tibet Aim Pharm Inc. The current willr is -2.52525253.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Tibet Aim Pharm Inc Daily Williams %R ChartTibet Aim Pharm Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Tibet Aim Pharm Inc.

Tibet Aim Pharm Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Tibet Aim Pharm Inc. The current atr is 0.38615271.

Tibet Aim Pharm Inc Daily Average True Range (ATR) ChartTibet Aim Pharm Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Tibet Aim Pharm Inc. The current obv is -113,822,844.

Tibet Aim Pharm Inc Daily On-Balance Volume (OBV) ChartTibet Aim Pharm Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Tibet Aim Pharm Inc. The current mfi is 64.54.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Tibet Aim Pharm Inc Daily Money Flow Index (MFI) ChartTibet Aim Pharm Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Tibet Aim Pharm Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-25STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-31BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-18WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-20MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-22STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.

6.3. Candlestick Patterns

Tibet Aim Pharm Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Tibet Aim Pharm Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.955
Ma 20Greater thanMa 508.272
Ma 50Greater thanMa 1008.211
Ma 100Greater thanMa 2009.639
OpenGreater thanClose8.880
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Tibet Aim Pharm Inc with someone you think should read this too:
  • Are you bullish or bearish on Tibet Aim Pharm Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Tibet Aim Pharm Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Tibet Aim Pharm Inc

I send you an email if I find something interesting about Tibet Aim Pharm Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Tibet Aim Pharm Inc.

Receive notifications about Tibet Aim Pharm Inc in your mailbox!